Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.

ABSTRACT: In 2017, facing lack of progress and failures encountered in targeted drug development for Autism Spectrum Disorder (ASD) and related neurodevelopmental disorders, the ISCTM with the ECNP created the ASD Working Group charged to identify barriers to progress and recommending research strategies for the field to gain traction. Working Group international academic, regulatory and industry representatives held multiple in-person meetings, teleconferences, and subgroup communications to gather a wide range of perspectives on lessons learned from extant studies, current challenges, and paths for fundamental advances in ASD therapeutics. This overview delineates the barriers identified, and outlines major goals for next generation biomedical intervention development in ASD. Current challenges fo

SUBMITTER: McCracken JT 

PROVIDER: S-EPMC10062405 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature